针对 Hedgehog（Hh）通路的急性髓系白血病治疗。
Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment.
机构信息
Department of Hematology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan.
Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa 296-8602, Japan.
出版信息
Cells. 2019 Apr 3;8(4):312. doi: 10.3390/cells8040312.
The Hedgehog (Hh) pathway, containing the Patched (PTCH) and Smoothened (SMO) multitransmembrane proteins, is the main regulator of vertebrate embryonic development. A non-canonical Hh pathway was recently observed in numerous types of solid cancers and hematological malignancies. Although acute myeloid leukemia (AML) is a common and lethal myeloid malignancy, the chemotherapy for AML has not changed in the last three decades. The Hh pathway and other intracellular signaling pathways are important for the tumor cells' cycle or therapeutic resistance of AML cells. In this article, we will review the current trends in Hh pathway inhibitors for treating AML.
刺猬（Hh）信号通路，包含 patched（PTCH）和 smoothened（SMO）多跨膜蛋白，是脊椎动物胚胎发育的主要调节剂。最近在许多类型的实体瘤和血液恶性肿瘤中观察到了非经典的 Hh 信号通路。尽管急性髓系白血病（AML）是一种常见且致命的髓系恶性肿瘤，但过去三十年来，AML 的化疗并未改变。Hh 信号通路和其他细胞内信号通路对 AML 细胞的周期或治疗耐药性很重要。在本文中，我们将回顾 Hh 信号通路抑制剂治疗 AML 的最新趋势。
Zotero 插件